- Home
- RBOT vs QNCX Comparison
RBOT vs QNCX Comparison
Compare RBOT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- QNCX
- Stock Information
- Founded
- RBOT 2014
- QNCX 2012
- Country
- RBOT United States
- QNCX United States
- Employees
- RBOT N/A
- QNCX N/A
- Industry
- RBOT Medical Specialities
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RBOT Health Care
- QNCX Health Care
- Exchange
- RBOT Nasdaq
- QNCX Nasdaq
- Market Cap
- RBOT 61.4M
- QNCX 85.9M
- IPO Year
- RBOT N/A
- QNCX 2019
- Fundamental
- Price
- RBOT $5.84
- QNCX $1.60
- Analyst Decision
- RBOT Hold
- QNCX Strong Buy
- Analyst Count
- RBOT 1
- QNCX 6
- Target Price
- RBOT $7.00
- QNCX $8.00
- AVG Volume (30 Days)
- RBOT 37.9K
- QNCX 124.9K
- Earning Date
- RBOT 11-11-2025
- QNCX 11-12-2025
- Dividend Yield
- RBOT N/A
- QNCX N/A
- EPS Growth
- RBOT N/A
- QNCX N/A
- EPS
- RBOT N/A
- QNCX N/A
- Revenue
- RBOT N/A
- QNCX N/A
- Revenue This Year
- RBOT N/A
- QNCX N/A
- Revenue Next Year
- RBOT N/A
- QNCX N/A
- P/E Ratio
- RBOT N/A
- QNCX N/A
- Revenue Growth
- RBOT N/A
- QNCX N/A
- 52 Week Low
- RBOT $5.00
- QNCX $0.69
- 52 Week High
- RBOT $19.00
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- RBOT 38.65
- QNCX 47.89
- Support Level
- RBOT $5.58
- QNCX $1.56
- Resistance Level
- RBOT $5.99
- QNCX $1.65
- Average True Range (ATR)
- RBOT 0.41
- QNCX 0.07
- MACD
- RBOT 0.06
- QNCX 0.00
- Stochastic Oscillator
- RBOT 19.12
- QNCX 64.65
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.